Company history

Pola began in 1929 as a one-man business. In Shizuoka, at a time when cosmetics reached buyers face-to-face across the counters of department stores and retail shops — the trade of established houses like Shiseido — Shinobu Suzuki chose the opposite: sending salespeople to a customer’s home to read her skin by age and season and choose products for it. The heterodox part was where the value sat. Rather than lining goods up in a shop and waiting for buyers, Pola built as its asset the customer ledger itself — who had what skin, and what had been sold to her — and that record of counseling sales would underwrite Pola’s earnings for generations.

Structure came early. In 1940 the individual business was incorporated as Pola Cosmetics Honpo (today Pola Chemical Industries); after the war, in 1946, Suzuki split selling from making by setting up a separate sales company, Pola Shoji (today Pola Inc.). That two-layer division — manufacturing in one house, a sales force organized in another — became a founding habit: keep the parts of the business that answer to different logics in separate vessels.

In 1954 the founder’s eldest son, Tsuneshi Suzuki, took the presidency and held it for some forty-two years, driving both the national rollout and the first moves abroad. The idea was to export the door-to-door model itself — an export contract in Hong Kong in 1958, a Thai subsidiary in 1967, a Hong Kong company in 1974 — and through the 1960s and 1970s Pola set up local arms across Asia, carrying its home-visit counseling into markets that had never seen it.

In 1984 Tsuneshi Suzuki did something a strong company rarely does: he stood up, inside the group, a model at odds with its own strength. Orbis was a separate mail-order company — cosmetics sold without a face-to-face meeting, which for a house built on door-to-door selling came close to a denial of the founding trade. Rather than shut the new channel out to protect the old one, he separated name and organization so the two could coexist, taking in the customers Pola had been letting slip without injuring its heritage. Orbis mailed samples for customers to try at home, and went nationwide by 1988.

Both arms then modernized their touchpoints. Pola launched its APEX-i order-system skincare in 1989, with salespeople building prescriptions from a customer’s skin-measurement data, and pushed APEX-i counters into department stores — loosening the reliance on home visits alone. Orbis moved the other way, out ahead of the industry: Orbis the Net went live in 1999 and the first Orbis the Shop opened in 2000, carrying a mail-order brand into e-commerce and physical stores at once.

Leadership passed within the family in 1996, when Tsuneshi’s nephew Satoshi Suzuki became the third president. He consolidated twenty regional sales companies into a single Pola Sales in 2005 and launched Pola the Beauty, a salon format fusing esthetics with a cosmetics shop where the door-to-door staff now worked from a storefront; the group had also stepped onto the Chinese mainland in Shanghai in 2004. These were all ways of modernizing the counseling-sales model — and the groundwork for turning the group into a holding company.

In 2006 the group set up Pola Orbis Holdings as a pure holding company, with Satoshi Suzuki as its first president and Pola, Orbis, the maker Pola Chemical and a real-estate arm gathered beneath it. The point of the vessel was to run the incompatible — the face-to-face Pola and the non-face-to-face Orbis — as independent-P&L subsidiaries, each on its own logic, while capital allocation and brand-building rose to the holding company. It was the structural completion of the shift from family trade to a specialist holding group.

In 2010 Pola Orbis listed directly on the Tokyo Stock Exchange’s First Section, only about four years after formation — unusually fast — and put the capital toward overseas and multi-brand expansion. Using the holding company’s agility, it launched brands in-house (the sensitive-skin DECENCIA in 2007, then THREE, ITRIM and Amplitude) and, in 2012, acquired Australia’s organic-cosmetics maker Jurlique for about $285.8M (¥23bn) — its first full-scale overseas M&A. By the mid-2010s the group carried more than ten brands.

The engine of those years was Pola’s own counter. Wrinkle Shot, launched in 2017 as Japan’s first approved medicinal wrinkle-improvement quasi-drug, lifted Pola’s department-store and directly-run sales to record-region profits. Yet the same year’s mid-term plan drew the first line of the other kind: it sorted brands into growth and core, divested the pdc and Future Labo businesses, and took impairments on the Jurlique intangibles and on drug-licensing rights — the beginning of a narrowing back toward a cosmetics core.

The lean years turned into a program of subtraction. Between 2018 and 2020 the group restructured its overseas brands under a plan to raise profitability: it decided to pull Jurlique out of China and completed the full divestment of its pharmaceutical business in early 2019, processing the impairments and disposal losses together to converge the portfolio onto cosmetics alone.

The pandemic then hit hard, and revenue fell in 2020. That year Miki Oikawa became president of Pola — the first woman to lead a major Japanese cosmetics maker — and in 2021 the group bought Torico, maker of the personalized brand FUJIMI, stepping into made-to-measure cosmetics. In 2022 it set out a long-range VISION 2029, casting itself as “a collective of distinctive businesses answering the diversifying values of beauty” rather than a single brand.

At the end of 2022 Satoshi Suzuki handed the presidency to Kiichi Yokote, a long-time overseas-business executive who took office in January 2023 — the founding family’s third generation giving way to a professional manager, with Suzuki staying on as a chairman holding representative authority. Yokote’s 2024–2026 mid-term plan runs exit and creation in parallel: it exits Amplitude and ITRIM to concentrate on THREE and winds down the China network, even as it opens new ventures in 2024 — encyclo, a beauty business for cancer survivors, and a travel-retail arm. Jurlique’s return to profit is set for 2026, the plan’s final year, and whether the group can stanch its overseas and Chinese loss-makers by then, with revenue still well below the pre-pandemic peak, is the near-term question.